Neurogene Inc (NGNE NASDAQ) stock market data APIs
$31.1447
1.05(3.4%)
as of May 7, 2026
Try our APIs with
free plan!
Neurogene Inc Financial Data Overview
Price chart is built with
Anychart
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Prev. Close
31.1447
Open
32.1957
High
33.7104
Low
29.8862
52 wk Range
13.93-37.2659
Market Cap
488 M
Shares Outstanding
15 616 K
EPS
-1.13
Beta
2.081
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Neurogene Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurogene Inc data using free add-ons & libraries
Get Neurogene Inc Fundamental Data
Neurogene Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -100 116 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-24
- EPS/Forecast: -1.2375
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurogene Inc News
New
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
NEW YORK, March 11, 2026--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurologic...
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Neurogene Gets FDA Breakthrough Tag For NGN-401 In Rett Syndrome; Stock Up
(RTTNews) - Neurogene Inc. (NGNE) announced that the U.S. FDA has granted Breakthrough Therapy designation to NGN-401, its investigational gene therapy for Rett syndrome. Rett syndrome is a rare, dev...
After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers
(RTTNews) - Several biotech and healthcare names posted notable gains in after-hours trading on Friday, with investors showing renewed interest in companies tied to drug development, healthcare servic...
Get Neurogene Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
